يعرض 1 - 11 نتائج من 11 نتيجة بحث عن '"Amy E Bock"', وقت الاستعلام: 0.62s تنقيح النتائج
  1. 1
    Academic Journal
    Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis

    المؤلفون: Jonathan Kay, Muhammad Rehman, Noriko Iikuni, Daniel F Alvarez, Amy E Bock, Wuyan Zhang

    المصدر: RMD Open, Vol 8, Iss 2 (2022)

    مصطلحات موضوعية: Medicine

    وصف الملف: electronic resource

    Relation: https://rmdopen.bmj.com/content/8/2/e002423.full; https://doaj.org/toc/2056-5933

    URL الوصول: https://doaj.org/article/47d8bc8df4e64e589a693cd1f20f04d6

    View record in DOAJ Full Text Finder

    أضف إلى المفضلة
  2. 2
    Academic Journal
    Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293

    المؤلفون: Rieke Alten, Carol Cronenberger, Daniel F Alvarez, Amy E Bock, Ivana Vranic, Wuyan Zhang

    المصدر: RMD Open, Vol 7, Iss 2 (2021)

    مصطلحات موضوعية: Medicine

    وصف الملف: electronic resource

    Relation: https://rmdopen.bmj.com/content/7/2/e001578.full; https://doaj.org/toc/2056-5933

    URL الوصول: https://doaj.org/article/7b89df7d1f944a94a3f3b1c2fa434ccb

    View record in DOAJ Full Text Finder

    أضف إلى المفضلة
  3. 3
    Academic Journal
    Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial

    المؤلفون: Roy M. Fleischmann, Daniel F. Alvarez, Amy E. Bock, Carol Cronenberger, Ivana Vranic, Wuyan Zhang, Rieke Alten

    المصدر: Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-11 (2021)

    مصطلحات موضوعية: Adalimumab, Adalimumab-afzb, Biosimilar, PF-06410293, Rheumatoid arthritis, Long-term, Diseases of the musculoskeletal system, RC925-935

    وصف الملف: electronic resource

    Relation: https://doaj.org/toc/1478-6362

    URL الوصول: https://doaj.org/article/0ee2953ecc944c48b52581e98907ed2d

    View record in DOAJ Full Text Finder

    أضف إلى المفضلة
  4. 4
    Academic Journal
    Additional file 2 of Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial

    المؤلفون: Roy M. Fleischmann (11480504), Daniel F. Alvarez (11480507), Amy E. Bock (11480510), Carol Cronenberger (5636501), Ivana Vranic (11480513), Wuyan Zhang (11480516), Rieke Alten (52012)

    مصطلحات موضوعية: Medicine, Pharmacology, Ecology, Immunology, Cancer, Infectious Diseases, Virology, Biological Sciences not elsewhere classified, Adalimumab, Adalimumab-afzb, Biosimilar, PF-06410293, Rheumatoid arthritis, Long-term, Switch, Safety

    Relation: https://figshare.com/articles/journal_contribution/Additional_file_2_of_Long-term_efficacy_safety_and_immunogenicity_of_the_adalimumab_biosimilar_PF-06410293_in_patients_with_rheumatoid_arthritis_after_switching_from_reference_adalimumab_Humira_or_continuing_biosimilar_therapy_week_52_92_da/16681313

    الاتاحة: https://doi.org/10.6084/m9.figshare.16681313.v1

    View record in BASE

    أضف إلى المفضلة
  5. 5
    Academic Journal
    Additional file 1 of Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial

    المؤلفون: Roy M. Fleischmann (11480504), Daniel F. Alvarez (11480507), Amy E. Bock (11480510), Carol Cronenberger (5636501), Ivana Vranic (11480513), Wuyan Zhang (11480516), Rieke Alten (52012)

    مصطلحات موضوعية: Medicine, Pharmacology, Ecology, Immunology, Cancer, Infectious Diseases, Virology, Biological Sciences not elsewhere classified, Adalimumab, Adalimumab-afzb, Biosimilar, PF-06410293, Rheumatoid arthritis, Long-term, Switch, Safety

    Relation: https://figshare.com/articles/journal_contribution/Additional_file_1_of_Long-term_efficacy_safety_and_immunogenicity_of_the_adalimumab_biosimilar_PF-06410293_in_patients_with_rheumatoid_arthritis_after_switching_from_reference_adalimumab_Humira_or_continuing_biosimilar_therapy_week_52_92_da/16681310

    الاتاحة: https://doi.org/10.6084/m9.figshare.16681310.v1

    View record in BASE

    أضف إلى المفضلة
  6. 6
    Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis

    المؤلفون: Roy M. Fleischmann, Amy E. Bock, Wuyan Zhang, Charles M. Godfrey, Ivana Vranic, Carol Cronenberger, Eva Dokoupilová

    المصدر: Rheumatology and Therapy. 9:839-850

    مصطلحات موضوعية: Rheumatology, Immunology and Allergy

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c58f54ca73100780cd84f9a908a6a456
    https://doi.org/10.1007/s40744-022-00439-8

    View record in OpenAIRE

    أضف إلى المفضلة
  7. 7
    Academic Journal
    A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

    المؤلفون: Roy M. Fleischmann, Rieke Alten, Margarita Pileckyte, Kasia Lobello, Steven Y. Hua, Carol Cronenberger, Daniel Alvarez, Amy E. Bock, K. Lea Sewell

    المصدر: Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-12 (2018)

    مصطلحات موضوعية: Rheumatoid arthritis, Adalimumab, Biosimilar, Comparative clinical study, Diseases of the musculoskeletal system, RC925-935

    Relation: http://link.springer.com/article/10.1186/s13075-018-1676-y; https://doaj.org/toc/1478-6362; https://doaj.org/article/1d4bd355220e4ba2b38cbe7e573f3370

    الاتاحة: https://doi.org/10.1186/s13075-018-1676-y
    https://doaj.org/article/1d4bd355220e4ba2b38cbe7e573f3370

    View record in BASE Full Text Finder

    أضف إلى المفضلة
  8. 8
    Randomized, Open‐Label, Single‐Dose, Parallel‐Group Pharmacokinetic Study of PF‐06410293 (adalimumab‐afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects

    المؤلفون: Daniel F. Alvarez, Amy E. Bock, Carol Cronenberger, Donna S. Cox

    المصدر: Clinical Pharmacology in Drug Development

    مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Injections, Subcutaneous, Urology, Pharmaceutical Science, Original Manuscript, Bioequivalence, 030226 pharmacology & pharmacy, 03 medical and health sciences, 0302 clinical medicine, Pharmacokinetics, Adalimumab, medicine, Distribution (pharmacology), Humans, Pharmacology (medical), Dosing, Adverse effect, Biosimilar Pharmaceuticals, bioequivalence, business.industry, Syringes, PF‐06410293, Articles, Middle Aged, Confidence interval, Healthy Volunteers, Injection Site Reaction, Tolerability, 030220 oncology & carcinogenesis, Female, business, pharmacokinetics, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75b9a3db92320f28eedc549db2b87384
    http://europepmc.org/articles/PMC8518774

    View record in OpenAIRE

    أضف إلى المفضلة
  9. 9
    AB0289 EFFICACY, SAFETY AND IMMUNOGENICITY IN PATIENTS WITH RHEUMATOID ARTHRITIS COMPARING PF-06410293 (ADL-PF), AN ADALIMUMAB (ADL) BIOSIMILAR, AND REFERENCE ADL: RESULTS FROM WEEK 26–52 OF A DOUBLE-BLIND, RANDOMISED PHASE 3 STUDY INCLUDING PATIENTS WHO SWITCHED FROM ADL-PF TO REFERENCE ADL AT WEEK 26

    المؤلفون: Roy Fleischmann, Wuyan Zhang, Carol Cronenberger, Amy E. Bock, Ivana Vranic, Daniel F. Alvarez, Rieke Alten

    المصدر: Annals of the Rheumatic Diseases. 79:1443.1-1444

    مصطلحات موضوعية: 0301 basic medicine, medicine.medical_specialty, Immunology, Phases of clinical research, General Biochemistry, Genetics and Molecular Biology, law.invention, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Randomized controlled trial, law, Internal medicine, medicine, Clinical endpoint, Adalimumab, Immunology and Allergy, media_common.cataloged_instance, European union, media_common, 030203 arthritis & rheumatology, business.industry, Biosimilar, medicine.disease, 030104 developmental biology, Rheumatoid arthritis, business, Rheumatism, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::2fa1476b37a8331d9c62bf9c83d88444
    https://doi.org/10.1136/annrheumdis-2020-eular.279

    View record in OpenAIRE

    أضف إلى المفضلة
  10. 10
    AB0285 RANDOMIZED, OPEN-LABEL, SINGLE-DOSE, PARALLEL-GROUP PHARMACOKINETIC STUDY OF PF-06410293, AN ADALIMUMAB BIOSIMILAR, BY SUBCUTANEOUS DOSING USING A PREFILLED SYRINGE OR A PREFILLED PEN IN HEALTHY SUBJECTS

    المؤلفون: Amy E. Bock, Daniel F. Alvarez, Carol Cronenberger, Donna S. Cox

    المصدر: Annals of the Rheumatic Diseases. 79:1441.2-1442

    مصطلحات موضوعية: 0301 basic medicine, medicine.medical_specialty, Immunology, Cmax, Bioequivalence, General Biochemistry, Genetics and Molecular Biology, law.invention, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Randomized controlled trial, Pharmacokinetics, law, Internal medicine, Immunology and Allergy, Medicine, media_common.cataloged_instance, Dosing, European union, Adverse effect, media_common, 030203 arthritis & rheumatology, business.industry, 030104 developmental biology, Tolerability, business

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::5dfa04eaad7d4376c84cff020d62a46e
    https://doi.org/10.1136/annrheumdis-2020-eular.454

    View record in OpenAIRE

    أضف إلى المفضلة
  11. 11
    THU0182 A comparative clinical study of pf-06410293, a candidate adalimumab biosimilar, and reference adalimumab for the treatment of active rheumatoid arthritis

    المؤلفون: Steven Y. Hua, Amy E. Bock, Roy Fleischmann, K.L. Sewell, Carol Cronenberger, Rieke Alten, Margarita Pileckyte

    المصدر: THURSDAY, 14 JUNE 2018.

    مصطلحات موضوعية: medicine.medical_specialty, education.field_of_study, business.industry, Population, medicine.disease, Rheumatology, Confidence interval, Rheumatoid arthritis, Internal medicine, medicine, Adalimumab, Clinical endpoint, Methotrexate, education, business, Rheumatism, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::5ef73ccdf10035b90ccb7f7fcd8b549d
    https://doi.org/10.1136/annrheumdis-2018-eular.1359

    View record in OpenAIRE

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء